Anchor Investment Management LLC Sells 6,349 Shares of Pfizer Inc. $PFE

Anchor Investment Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 133,115 shares of the biopharmaceutical company’s stock after selling 6,349 shares during the period. Anchor Investment Management LLC’s holdings in Pfizer were worth $3,373,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in PFE. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. Triumph Capital Management lifted its stake in Pfizer by 20.0% in the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 1,717 shares during the last quarter. Gotham Asset Management LLC lifted its stake in Pfizer by 333.4% in the fourth quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company’s stock worth $3,742,000 after purchasing an additional 108,494 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Pfizer by 80.7% in the fourth quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock worth $25,434,000 after purchasing an additional 427,886 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.8%

PFE stock opened at $24.74 on Wednesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a market capitalization of $140.66 billion, a price-to-earnings ratio of 13.16, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55. The business’s 50 day moving average price is $24.85 and its two-hundred day moving average price is $24.33. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio is 91.49%.

Analysts Set New Price Targets

Several brokerages have recently commented on PFE. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank lowered their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.